These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 34207510)

  • 1. Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms.
    Montero P; Milara J; Roger I; Cortijo J
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease.
    Huo R; Guo Q; Hu J; Li N; Gao R; Mi L; Zhang Z; Liu H; Guo Z; Zhao H; Zhang L; Xu K
    Drug Des Devel Ther; 2022; 16():991-998. PubMed ID: 35400994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension.
    Roger I; Milara J; Montero P; Cortijo J
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease.
    Talotta R
    Immunotherapy; 2021 Feb; 13(3):241-256. PubMed ID: 33410346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms.
    Liu J; Wang F; Luo F
    Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    Lai SY; Johnson FM
    Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
    Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
    Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
    Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
    Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
    Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
    Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
    Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
    Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
    Coskun M; Salem M; Pedersen J; Nielsen OH
    Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
    Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
    Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors.
    Welsch K; Holstein J; Laurence A; Ghoreschi K
    Eur J Immunol; 2017 Jul; 47(7):1096-1107. PubMed ID: 28555727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mining for JAK-STAT mutations in cancer.
    Constantinescu SN; Girardot M; Pecquet C
    Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
    Yang X; Tang Z; Zhang P; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The JAK/STAT signaling pathway: from bench to clinic.
    Hu X; Li J; Fu M; Zhao X; Wang W
    Signal Transduct Target Ther; 2021 Nov; 6(1):402. PubMed ID: 34824210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatment with resveratrol alleviates adjuvant arthritis-interstitial lung disease in rats via modulation of JAK/STAT/RANKL signaling pathway.
    Yang G; Lyu L; Wang X; Bao L; Lyu B; Lin Z
    Pulm Pharmacol Ther; 2019 Jun; 56():69-74. PubMed ID: 30930172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of the Jak/STAT pathway.
    Aittomäki S; Pesu M
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):18-23. PubMed ID: 24164900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Baricitinib on the epithelial-mesenchymal transition of alveolar epithelial cells induced by IL-6.
    Liu Y; Hu M; Fan G; Xing N; Zhang R
    Int Immunopharmacol; 2022 Sep; 110():109044. PubMed ID: 35850052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Liuweibuqi Capsules in Pulmonary Alveolar Epithelial Cells and COPD Through JAK/STAT Pathway.
    Wang C; Ding H; Tang X; Li Z; Gan L
    Cell Physiol Biochem; 2017; 43(2):743-756. PubMed ID: 28950251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.